News Releases
by Year
2022
Oct. 03, 2022 (PDF/601KB) Corporate
Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
Sep. 30, 2022 (PDF/407KB) Licensing
Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
Sep. 29, 2022 (PDF/160KB) R&D
Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem- Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
Sep. 27, 2022 (PDF/183KB) Corporate
Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
Sep. 02, 2022 (PDF/585KB) Corporate
Sumitomo Pharma Announces Personnel Changes
Aug. 31, 2022 (PDF/477KB) Sustainability
Sumitomo Pharma Selected for Inclusion as a Constituent of Five GPIF-Adopted ESG Indexes that Cover Japanese Stocks
Aug. 08, 2022 (PDF/272KB) Products
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Aug. 03, 2022 Finances
Posted Conference Call for Q1 FY2022 [Webcast]
Aug. 03, 2022 (PDF/162KB) Licensing
Notice of conclusion of sales collaboration for GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos"
Jul. 29, 2022 (PDF/413KB) Finances
Presentation Material（First Quarter Financial Results for FY2022）
Jul. 29, 2022 (PDF/333KB) Finances
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2023
Jul. 29, 2022 (PDF/244KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2023 [IFRS]
Jul. 29, 2022 (PDF/136KB) Finances
Notice Concerning Finance Income
Jul. 13, 2022 (PDF/272KB) Corporate
Notice of Relocation of Tokyo Head Office
Jul. 06, 2022 (PDF/212KB) Licensing
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
Jun. 29, 2022 (PDF/146KB) Corporate
(Update on Disclosed Matter) Notice of Establishment of Holding Company in China
Jun. 03, 2022 (PDF/91KB) R&D
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE
May 23, 2022 Finances
Posted Video of Investors Meeting Presentation for FY2021 [Webcast]
May 13, 2022 (PDF/1,158KB) Finances
Investors Meeting Presentation for FY2021 (Year ended March 31, 2022)
May 13, 2022 (PDF/307KB) Finances
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022
May 13, 2022 (PDF/276KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2022 [IFRS]
May 13, 2022 (PDF/171KB) Corporate
Sumitomo Pharma Announces Changes in Board of Directors and Audit & Supervisory Board
May 10, 2022 (PDF/42KB) Licensing
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 09, 2022 (PDF/251KB) R&D
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis
May 05, 2022 (PDF/204KB) Licensing
Sumitomo Pharma and Jazz Pharmaceuticals Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
May 02, 2022 (PDF/40KB) Products
Myovant Sciences Announces European Commission Approval for ORGOVYX (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Apr. 28, 2022 (PDF/164KB) Finances
Sumitomo Pharma Announces Revisions to Its Financial Forecasts
Apr. 22, 2022 (PDF/148KB) Corporate
Sumitomo Pharma Builds Cell-Processing Center in U.S.
Apr. 12, 2022 (PDF/255KB) R&D
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated with Endometriosis
Apr. 08, 2022 (PDF/129KB) Sustainability
Switch to 100% Renewable Energy for Electric Power Purchased by Suzuka Plant
Apr. 04, 2022 (PDF/143KB) Finances
Notification of Valuation Loss on Investment Securities Recorded in Company's Non-consolidated Financial Statements (Japanese GAAP)
Apr. 01, 2022 (PDF/197KB) Corporate
Notice of Change of the Trade Name
Mar. 31, 2022 (PDF/410KB) R&D
National Cancer Center Japan, Shonai Regional Industry Promotion Center and Sumitomo Dainippon Pharma Announce Start of Phase 1/2 Study on New Drug Candidate Compound in Acute Myeloid Leukemia
Mar. 30, 2022 (PDF/103KB) Corporate
Notice of Establishment of Holding Company in China
Mar. 22, 2022 (PDF/119KB) Sustainability
Sumitomo Dainippon Pharma Provides Material Assistance to Ukraine
Mar. 16, 2022 (PDF/121KB) Sustainability
Sumitomo Dainippon Pharma Enacts Basic Policy for Respecting Human Rights
Mar. 11, 2022 (PDF/123KB) Corporate
Sumitomo Dainippon Pharma Announces Additional Investment in Aikomi Ltd.
Mar. 03, 2022 (PDF/4,357KB) Finances
Sumitomo Chemical Announces the New Corporate Business Plan FY2022 - FY2024
Mar. 02, 2022 (PDF/139KB) Corporate
Sumitomo Dainippon Pharma Announces Changes in Executive Officers Including Representative Director, Organizational Realignment and Personnel Changes
Mar. 01, 2022 (PDF/171KB) Licensing
JCR and Sumitomo Dainippon Pharma Enter into Marketing Alliance for Agalsidase Beta BS I.V. Infusion [JCR], for Treatment of Fabry Disease in Japan
Feb. 28, 2022 (PDF/45KB) R&D
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer
Feb. 07, 2022 Finances
Posted Conference Call for Q3 FY2021 [Webcast]
Jan. 31, 2022 (PDF/1,158KB) Finances
Presentation Material（Third Quarter Financial Results for FY2021）
Jan. 31, 2022 (PDF/305KB) Finances
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022
Jan. 31, 2022 (PDF/520KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2022 [IFRS]
Jan. 13, 2022 (PDF/173KB) R&D
Kitasato Institute and Sumitomo Dainippon Pharma Start Phase 1 Study on New Drug Candidate Compound Discovered in Joint Research as Treatment for Carbapenem-resistant Bacterial Infections